Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis

Seok Jin Kim¹⁺, Hyun-Tae Shin²⁺, Hae-Ock Lee²⁺, Nayoung K.D. Kim², Jae Won Yun², Jee Hyang Hwang³, Kihyun Kim¹, Woong-Yang Park²

¹Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
²Samsung Genome Institute, Samsung Medical Center, Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Seoul, Korea
³Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea

*Co-first authors, these authors contributed equally to this work

Correspondence to: Kihyun Kim, email: kihyun.kim@samsung.com
Woong-Yang Park, email: woongyang.park@samsung.com

Keywords: multiple myeloma, cancer panel, MAPK pathway, amyloidosis

Received: March 31, 2016  Accepted: August 10, 2016  Published: September 15, 2016

ABSTRACT

Clinically applicable platforms revealing actionable genomic alterations may improve the treatment efficacy of myeloma patients. In this pilot study, we used a high depth targeted sequencing panel containing 83 anti-cancer drug target genes to sequence genomic DNAs extracted from bone marrow aspirates of 23 patients with myeloma and 12 patients with amyloid light-chain (AL) amyloidosis. Mutation analysis revealed NRAS as the most commonly mutated gene (30%, 7/23) in myeloma patients followed by KRAS (26%, 6/23) and BRAF (22%, 5/23). However, no significant mutations were found in the 12 patients with AL amyloidosis. Notably, 6 of the 23 myeloma patients showed multi-site and/or multi-gene mutations in NRAS, KRAS, or BRAF, indicating compound aberrations in the Mitogen activated protein kinase (MAPK) pathway. Gene panel sequencing also revealed cytogenetic abnormalities associated with prognosis in myeloma patients. In conclusion, our pilot study suggests that targeted gene sequencing may have an important prognostic value for myeloma patients for the identification of actionable genomic alterations and cytogenetic aberrations.

INTRODUCTION

Since novel drugs such as proteasome inhibitors and immunomodulatory agents were first introduced for the treatment of multiple myeloma, survival outcomes have significantly improved [1–3]. However, multiple myeloma still remains an incurable disorder because almost all patients relapse and become refractory to salvage treatments [4, 5]. As treatment outcome may be associated with cytogenetic abnormalities at diagnosis, patients with multiple genetic alterations might show worse prognosis than patients without them [6, 7]. Genetic alterations may accumulate during the development of myeloma from asymptomatic monoclonal gammopathy of undetermined significance because myeloma cases are preceded by an asymptomatic expansion of clonal plasma cells [8, 9]. Amyloid light-chain (AL) amyloidosis is a rare clonal plasma cell disorder characterized by deposition of amyloid fibrils derived from immunoglobulin light chains in various organs [10]. AL amyloidosis and multiple myeloma are theoretically same disease entity at the cellular level, and AL amyloidosis was reported to share genetic susceptibility with multiple myeloma [11]. The presence of small plasma cell clones in AL amyloidosis implies that these clones could become larger, leading to overt multiple myeloma over time [12]. Thus, patients with myeloma may have heterogeneous subclones, and the identification of genetic abnormalities with low frequency in these subclones could be helpful for a better understanding of each patient with myeloma. However, it
is difficult to detect low frequency genetic alterations in small subclones by conventional molecular testing using malignant plasma cells from bone marrow. Genomic next generation sequencing (NGS) has allowed for a thorough exploration of the genetic alterations possible in myeloma [13, 14]. However, NGS is still not readily used in clinical practice because it is both a high cost and time-consuming process. Thus, the development of clinically applicable platforms revealing genomic alterations could help to improve a risk-adapted treatment strategy. Here, we performed a pilot study to evaluate the feasibility of a targeted gene sequencing panel consisting of 83 genes in myeloma and AL amyloidosis patients.

**RESULTS**

**Characteristics of patients**

A total of 35 patients was enrolled in this study; the median age at diagnosis was 60 years (range: 31–85). Patients were classified into one of three groups according to the percentage of plasma cells and the presence of organ amyloidosis and osteolytic lesions: myeloma \((n = 17)\), myeloma with AL amyloidosis \((n = 6)\), and AL amyloidosis \((n = 12)\). Thus, 17 patients who were diagnosed with myeloma had at least 10% malignant plasma cells in their bone marrow in conjunction with increased M protein in the serum and/or urine. With the exception of one patient, all myeloma only patients also had at least one sign or symptom related to myeloma such as renal dysfunction, anemia, or osteolytic bone lesion (Table 1). In the remaining 18 patients, the presence of amyloid depositions in various organs such as heart, kidney and gastrointestinal tract was pathologically confirmed; thus, they were diagnosed with AL amyloidosis. Six of these patients had ≥ 30% plasma cells in their bone marrow aspirates or had osteolytic lesions diagnosed as myeloma coupled with AL amyloidosis (Table 2). The clinical and laboratory characteristics of patients at diagnosis and their initial treatments and transplantations are summarized in Tables 1 and 2. The most commonly used treatment regimens were thalidomide, dexamethasone with or without cyclophosphamide \((n = 13)\), and bortezombib, melphalan and prednisone \((n = 9)\). Bortezomib-containing treatment was used for patients ineligible for autologous stem cell transplant (ASCT), whereas thalidomide-containing treatment was done for patients eligible for ASCT. Thus, ASCT was done in 13 patients as a part of the induction treatment. At the time of analysis, 26 patients were alive, while nine patients died from myeloma \((n = 4)\), AL amyloidosis \((n = 2)\), or myeloma with AL amyloidosis \((n = 3)\). The overall survival was not significantly different among the three groups (Figure 1A). When patients with AL amyloidosis were grouped together regardless of myeloma, the comparison of overall survival was not different either (Figure 1A).

**Mutations in myeloma and AL amyloidosis**

Patients were genotyped using high depth panel sequencing with a mean depth of coverage, 846× (Supplementary Table S1). Mutation analysis of all myeloma patients including the six patients with AL amyloidosis revealed NRAS as the most commonly mutated gene (30%, 7/23), followed by KRAS (26%, 6/23) and BRAF (22%, 5/23) (Figure 1B). One patient (patient #1, Table 3) showed multiple mutations in NRAS, KRAS, and BRAF, and two other patients (patients #2 and #23, Table 3) showed BRAF mutations with either NRAS or KRAS. Three patients showed multi-site mutations in the KRAS or BRAF gene (patients #6, #7, and #10, Table 3). However, no significant mutations were found in the 12 patients with AL amyloidosis alone, although mutations were found in myeloma with AL amyloidosis (Figure 1B). Although some patients showed more than 30% allele frequency, the majority of mutations in the three genes showed low variant allele fractions (around 5%). Mutations in BRAF and KRAS were verified using droplet digital PCR (ddPCR), and the values of allele frequency from the 7 patients harboring low allele fraction (≤ 10%) mutations were highly correlated with those of ddPCR \((r = 0.95)\) (Figure 2). Thus, the application of a targeted gene sequencing panel in myeloma patients identified mutations in mitogen activated protein kinase (MAPK) pathway-related genes (KRAS, NRAS, and BRAF). Interestingly, the low allele frequency mutations were detected in separate sequence reads from those with high allele frequency mutations (Supplementary Figure S1), demonstrating the ongoing alteration of MAPK pathway for the wild type tumor populations. These data suggest that the high sensitivity of our panel sequencing platform could allow for early detection of subclones with clinical significance.

**Copy number variations in myeloma and AL amyloidosis**

In addition to mutational analysis, gene panel sequencing was used to detect chromosomal copy number variations (CNV), which are often associated with prognosis in myeloma patients. Three types of CNV were detected in myeloma patients in a mutually exclusive manner, while amyloidosis patients had scarcely any changes (Figure 3A). The three CNVs in myeloma patients were amplification of chromosome 1q, amplification of odd number chromosomes (hyperdiploidy), and deletion of chromosome 13q. In particular, the chromosome 13q deletion was frequently detected in patients with the dual diagnosis of myeloma and amyloidosis (5 out of 6). Notably, chromosome 1q amplification and 13q deletion are associated with poor prognosis in multiple myeloma [15, 16]. The CNV calls made from gene panel sequencing showed a significant
Table 1: Characteristics and outcomes of patients with myeloma

| No. | S/A | Type | Osteolytic lesion | Plasmacytoma | Hgb < 10 g/dL | Ca > 11.5 mg/dL | LDH increased | BM PC% | ISS | Induction treatment | Response to induction | ASCT | Survival status | OS (months) |
|-----|-----|------|------------------|--------------|---------------|----------------|---------------|--------|-----|--------------------|---------------------|------|----------------|-------------|
| 1   | M/46| λ    | Presence         | Presence     | 70            | I              | VD            | PD     | 1   | VMP                | PD                  | Dead | 23             |
| 2   | F/75| IgG, λ | Presence | Presence | 90            | II             | VMP           | PD     | 21  |
| 3   | M/68| IgA, λ | Presence | Presence | 60            | II             | VMP           | CR     | 18  |
| 4   | M/74| λ    | Presence         | Presence | 100           | III            | VMP           | PD     | 20  |
| 5   | M/76| IgG, κ | Presence | Presence | 10            | 1              | None          | NA     | 17  |
| 6   | F/48| IgG, κ | Presence | Presence | 40            | I              | VAD           | PR     | Single | Alive | 68 |
| 7   | F/31| IgG, κ | Presence | Presence | 35            | I              | TD            | PD     | Tandem | Dead | 14 |
| 8   | M/71| IgG, κ | Presence | Presence | 60            | I              | VMP           | SD     | 21  |
| 9   | M/51| IgG, κ | Presence | Presence | 23            | II             | TD            | CR     | Single | Dead | 20 |
| 10  | M/42| IgG, λ | Presence | Presence | 50            | II             | TD            | VGPR   | Single | Alive | 22 |
| 11  | F/85| IgG, κ | Presence | Presence | 60            | II             | VMP           | SD     | 23  |
| 12  | M/63| IgM, κ | Presence | Presence | 50            | I              | TD            | PD     | Tandem | Dead | 22 |
| 13  | F/68| κ    | Presence | Presence | 40            | I              | VMP           | CR     | Alive | 22 |
| 14  | F/54| IgG, κ | Presence | Presence | 16            | II             | TD            | SD     | Single | Alive | 33 |
| 15  | F/66| IgG, κ | Presence | Presence | 50            | II             | CMP           | PD     | 21  |
| 16  | M/77| IgG, λ | Presence | Presence | 100           | III            | VMP           | VGPR   | Alive | 20 |
| 17  | M/43| IgA, κ | Presence | Presence | 30            | II             | TCD           | PD     | Tandem | Dead | 29 |

S: sex; A: age; Hgb: hemoglobin; LDH: lactate dehydrogenase; BM: bone marrow; PC: plasma cell; DSS: ISS: International staging system; ASCT: autologous stem cell transplantation; OS: overall survival; VD: bortezomib, dexamethasone; VMP: bortezomib, melphalan, prednisone; VAD: vincristine, adriamycin, dexamethasone; TD: thalidomide, dexamethasone; CMP: carfilzomib, melphalan, prednisone; TCD: thalidomide, cyclophosphamide, dexamethasone; CR: complete response; VGPR: very good partial response; PR: partial response; SD: stable disease; PD: progressive disease.

correlation with those from the whole exome sequencing (Supplementary Figure S2), and a lower positive correlation with those from fluorescence in situ hybridization (FISH) data using a single probe (Figure 3B, 3C).

**Association of treatment response and NRAS/KRAS/BRAF mutation**

Among the seven patients with NRAS mutation, four patients (patients #1–4) were treated with bortezomib-containing treatment; three of these patients did not respond (Table 1). Thus, 75% (3/4) of patients showed disease progression during bortezomib treatment, although the sample size was small. Two patients with BRAF mutations also failed to show response to bortezomib; however, these patients (patients #1 and #2) both had NRAS mutations. Although only two patients with KRAS mutations received the bortezomib-containing treatment (patient #1, 8), neither responded to it. (One patient showed disease progression while the other maintained a stable disease state; Table 1). There was no significant association between the presence of the mutation and the response to other drugs such as thalidomide (data not shown).

**DISCUSSION**

In this study, we identified mutations in three well-known oncogenes, KRAS, NRAS, and BRAF, in multiple myeloma patients. No mutations were found in patients with AL amyloidosis alone, although patients with myeloma combined with AL amyloidosis did show mutations in all three genes (Figure 1B). The frequency of the mutations in the three genes identified in our study was consistent with those presented in a recent study of whole-exome sequencing in 463 patients with myeloma enrolled in the National Cancer Research Institute Myeloma XI trial, which reported a dominant mutation in the RAS (43%) [17]. Mutations in RAS gene family have been reported to show predominant mutational activation of one member of the RAS gene family. Solid tumors such as colorectal and pancreatic cancers showed frequent KRAS mutations, whereas some hematologic cancers such as acute lymphoblastic leukemia predominately showed NRAS mutations [18]. Unlike other malignancies, mutations of KRAS and NRAS were found in approximately equal rates in myeloma [19, 20]. Similarly, the frequency of mutations was similar between NRAS (30%, 7/23) and KRAS (26%, 6/23) in our study (Figure 1B). BRAF mutations (22%, 5/23) were also found in five myeloma patients including two patients with both AL amyloidosis and myeloma (Figure 1B). The BRAF mutation is known to be mutually exclusive with KRAS and/or NRAS mutations in other cancers [21]; however, in our study, mutations in BRAF did not appear to be exclusive to either the KRAS or NRAS mutation because mutations in KRAS, NRAS, and BRAF were all found in the same patient (patient #1, Table 3). Given that each RAS family member can provide a similar
oncogenic signal through the mitogen-activated protein kinase (MAPK) pathway promoting cell proliferation, the presence of these mutations could be expected to result in a worse treatment outcome than the absence of these mutations. Indeed, a previous study showed an association of NRAS mutations with a lower response rate to bortezomib and a shorter time to disease progression in bortezomib-treated patients [22]. In our study, patients with NRAS mutations showed poor response to bortezomib-containing treatments. Furthermore, the patient with mutation of three genes, KRAS, NRAS and BRAF (patient #1, Table 3) was primarily refractory to bortezomib, lenalidomide, and bendamustine-containing treatments. None of the mutations in the MAPK pathway-related genes were detected by conventional molecular tests at the time of initial diagnosis. Thus, a targeted sequencing such as our cancer panel may be useful for detecting low frequency genetic events, allowing for a predicted treatment response. As our patients with AL amyloidosis were mainly treated with thalidomide or alkylating agents, the association of the absence of the MAPK-pathway related gene mutations with the response to bortezomib could not be evaluated in this study (Table 2). However, our previous study with AL amyloidosis patients showed that sixteen of nineteen (84%) patients who were treated with bortezomib, melphalan, and prednisolone had a hematologic response, including seven complete responders [23]. These results support the association of MAPK pathway gene mutations with the response to bortezomib.

Our pilot study applied a targeted gene sequencing panel consisting of 83 genes that were selected based on the availability of corresponding targeting agents. Thus, the genes used for the targeted sequencing could be targeted by developed anti-cancer drugs. Furthermore, gene panel sequencing provided large numbers of mutations as well as chromosomal amplifications or deletions with an important prognostic value compared to the conventional cytogenetic and FISH methods. As there are discrepancies between gene panel sequencing and conventional cytogenetic/FISH methods, further improvement is required for the use of next generation sequencing for cytogenetic analysis.

Compared to myeloma and myeloma with AL amyloidosis, the results of AL amyloidosis showed no evidence of major mutations. Indeed, the clinical features and treatment outcomes were mainly correlated with the type and extent of organ involvement rather than the presence of specific genetic alterations.
Table 2: Characteristics and outcomes of patients with AL amyloidosis including myeloma with amyloidosis

| No. | S/A  | Type | Bone marrow involvement | Involved organ(s) | Hgb < 10 g/dL | LDH increased | BM PC% | ISS | Combined with MM | Induction treatment | Response to induction | ASCT | Survival status | OS (months) |
|-----|------|------|-------------------------|-------------------|--------------|---------------|---------|------|------------------|---------------------|---------------------|--------|-----------------|-------------|
| 18  | M/37 | κ    | Presence               | Heart, GI tract   | Presence     | 30            | II      | Yes  | TCD             | PR                  | Single              | Alive  | 40              |
| 19  | M/62 | IgG, κ | Presence             | Kidney            | Presence     | 100           | II      | Yes  | None            | NA                  | Dead                | 1      |
| 20  | M/57 | κ    | Presence               | Liver             | Presence     | 30            | II      | Yes  | TCD             | CR                  | Single              | Alive  | 34              |
| 21  | M/57 | κ    | Presence               | Heart             | Presence     | 30            | II      | Yes  | MD              | PD                  | Dead                | 4      |
| 22  | F/49 | κ    | Presence               | Liver             | Presence     | 50            | II      | Yes  | TD              | CR                  | Single              | 30     |
| 23  | M/71 | IgG, κ | Presence              | Heart             | Presence     | 20            | II      | Yes  | MD              | CR                  | Dead                | 27     |
| 24  | F/67 | IgG, κ | Presence              | Kidney            | Presence     | 20            | III     | Yes  | MD              | CR                  | Dead                | 21     |
| 25  | F/59 | λ    | Presence               | Heart             | Presence     | 15            | No      | MD   | VMP             | CR                  | Alive               | 36     |
| 26  | F/55 | κ    | Presence               | Lung              | Presence     | 15            | No      | TD   | PR              | Single              | Alive               | 28     |
| 27  | M/60 | λ    | Presence               | GI tract, Nerve   | Presence     | 5             | No      | None | NA              | Alive               | 26     |
| 28  | F/47 | IgG, λ |                 | Heart, Nerve     |              | 20            | No      | MD   | PD              | Dead                | 3      |
| 29  | M/77 | IgG, λ |                 | Heart             | Presence     | 15            | No      | None | NA              | Dead                | 3      |
| 30  | M/60 | κ    | Presence               | Liver, nerve      | Presence     | 15            | No      | TD   | PR              | Alive               | 14     |
| 31  | M/57 | λ    | Presence               | Heart, nerve      | Presence     | 12            | No      | TD   | SD              | Alive               | 20     |
| 32  | F/64 | IgA, λ |             | Heart, Nerve      | Presence     | 15            | No      | MD   | PR              | Alive               | 19     |
| 33  | M/43 | IgG, λ |             | Kidney            | Presence     | 4             | No      | None | CR              | Single              | 17     |
| 34  | M/64 | λ    | Presence               | Soft tissue       | Presence     | 15            | No      | TD   | PR              | Single              | 17     |
| 35  | M/77 | IgA, λ |             | Kidney, Heart, Nerve | Presence     | 20            | No      | VMP | SD              | Alive               | 17     |

S: sex; A: age; Hgb: hemoglobin; LDH: lactate dehydrogenase; BM: bone marrow; PC: plasma cell; DSS: Durie-Salmon stage; ISS: International staging system; ASCT: autologous stem cell transplantation; OS: overall survival; GI tract: gastrointestinal tract; TCD: thalidomide, cyclophosphamide, dexamethasone; MD: melphalan, dexamethasone; TD: thalidomide, dexamethasone; VMP: bortezomib, melphalan, prednisone; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NA: not applicable; MM: multiple myeloma.

Table 3: Amino acid changes and allele frequencies of three genes (KRAS, NRAS, and BRAF) in co-occurrence samples

| Sample | Amino acid change (variant allele frequency, %) |
|--------|-----------------------------------------------|
|        | NRAS                                         | KRAS                  | BRAF                  |
| #1     | G12A(1)                                      | Q61R(3)               | D594N(5)              |
| #2     | G13R(14)                                     | Q61K(2)               | D594G(4)              |
| #23    | G61L(18)                                     | Q61R(3)               | D594N(7)              |
| #6     | G12A(2)                                      | A146V(5)              | V600E(4)              |
| #7     | G12C(1)                                      | G13D(28)              | V600E(34)             |
| #10    | G13D(56)                                     | L19F(3)               | I714V(33)             |
|        |                                               |                       |                      |
Figure 2: High correlation of VAF from cancer panel and digital droplet PCR. (A) VAF from cancer panel and ddPCR (B) Scatter plot for VAF of cancer panel and ddPCR.

| No. | Gene | Variant | VAF (%) |
|-----|------|---------|---------|
| 1   | BRAF | D594N   | 5   | 5.1  |
| 2   | BRAF | D594G   | 3.8 | 3.1  |
| 7   | KRAS | G13D    | 56.0| 58.3 |
| 8   | KRAS | G12V    | 43.0| 43.3 |
| 10  | BRAF | I714V   | 33.2| 34.7 |
| 10  | BRAF | V600E   | 33.8| 33.9 |
| 18  | BRAF | V600E   | 7.0 | 6.9  |
| 23  | BRAF | D594N   | 7.0 | 8.9  |
| 23  | BRAF | V600E   | 4.0 | 3.4  |
| 23  | KRAS | A146V   | 4.9 | 4.1  |
| 23  | KRAS | G12A    | 1.8 | 1.5  |

Figure 3: Copy number variations estimated from gene panel sequencing. (A) Pearson’s correlation distances were used for the average-linkage hierarchical clustering of patients. Correlation analysis between the CNV estimation and FISH analysis for (B) chromosome 1q amplification and (C) chromosome 13q deletion.
Patients were diagnosed with myeloma according to the criteria by the International Myeloma Working Group [26]. Accordingly, genetic alterations could accumulate during the process of myeloma development and progression contributing to genetic heterogeneity of myeloma. This heterogeneity also might influence treatment outcomes of myeloma because certain clones with a given genetic mutations may be sensitive to one drug whereas a different clone having with a different genetic mutations may not respond to the drug, resulting in relapse or progression after treatment. Thus, the initial screening of the genetic mutation landscape for each myeloma patient at diagnosis may provide important information for subsequent treatment and follow-up of myeloma patients.

Nonetheless, our study has some limitations. First, our gene panel mainly consisted of genes covering targets of developed anti-cancer drugs. Given that the majority of targeted agents currently available focus on solid tumors, a substantial number of genes studied were related to solid tumor phenotypes rather than to myeloma. It is also possible that some patients had alterations in non-target regions. Second, we could not demonstrate an association of mutations in MAPK pathway-related genes (KRAS, NRAS and BRAF) with survival outcomes of our patients. Thus, further study with larger study populations and longer follow-ups are required to confirm the clinical utility of targeted sequencing. Recently, Kortum et al. investigated 72 untreated myeloma patients with deletion 17p using a myeloma-specific gene panel for targeted sequencing of 47 genes. They found a higher prevalence of TP53 mutation (28%) than previous studies. Nonetheless, our study has some limitations. First, our gene panel mainly consisted of genes covering targets of developed anti-cancer drugs. Given that the majority of targeted agents currently available focus on solid tumors, a substantial number of genes studied were related to solid tumor phenotypes rather than to myeloma. It is also possible that some patients had alterations in non-target regions. Second, we could not demonstrate an association of mutations in MAPK pathway-related genes (KRAS, NRAS and BRAF) with survival outcomes of our patients. Thus, further study with larger study populations and longer follow-ups are required to confirm the clinical utility of targeted sequencing. Recently, Kortum et al. investigated 72 untreated myeloma patients with deletion 17p using a myeloma-specific gene panel for targeted sequencing of 47 genes. They found a higher prevalence of TP53 mutation (28%) than previous studies and suggested that this targeted sequencing could provide a comprehensive insight into the mutational landscape of high-risk myeloma [27].

In conclusion, we present results of our pilot study with targeted genome sequencing for myeloma and AL amyloidosis. We believe that targeted gene panel sequencing will help to further improve myeloma diagnosis as well as track clonal heterogeneity. Furthermore, this diagnostic approach may provide more precise prognosis and better guidance for treatment decisions in myeloma patients.

**MATERIALS AND METHODS**

**Patients**

We enrolled consecutive patients who were diagnosed with multiple myeloma or AL amyloidosis at the Samsung Medical Center between 2013 and 2014. Patients were diagnosed with myeloma according to the presence of malignant plasma cells ≥ 10% of bone marrow aspirates and increased monoclonal proteins in serum and/or urine [28]. AL amyloidosis was diagnosed with the presence of amyloid deposits in involved organs, which was confirmed by Congo red staining and monoclonal protein in serum and/or urine. After obtaining informed consent from participating patients, we performed bone marrow aspiration. Plasma cells were isolated by magnetic separation using anti-CD138 microbeads and were stored at −80°C. The extent of disease in myeloma patients was determined using the International Staging System (ISS) consisting of serum albumin and beta-2 microglobulin [29]. All patients with myeloma received induction treatment with curative intent. Induction treatment was done with immunomodulatory agents or proteasome inhibitors according to the physicians’ discretion. After induction treatment, ASCT was done for eligible patients. To diagnose AL amyloidosis, patients receiving ASCT were < 65 years with adequate cardiac function. However, patients ineligible for ASCT received only an alkylating agent containing a chemotherapeutic agent such as melphalan or dexamethasone. The hematologic response to treatment was based on the revised uniform response criteria by the International Myeloma Working Group [30]. The survival and disease statuses were updated at the time of analysis; thus, the last update was done in March, 2016. All aspects of the study were reviewed and approved by the Institutional Review Board (IRB) of the Samsung Medical Center (No. 2012-08-059).

**Targeted sequencing**

Targeted sequencing was done using a customized cancer panel. Genomic DNA was extracted from tissue specimens using QIAamp DNA mini kit (Qiagen, Valencia, CA, USA). Genomic DNA quality and quantity were determined using a Nanodrop 8000 UV-Vis spectrometer (Thermo Scientific, Waltham, MA, USA), and a 2200 TapeStation Instrument (Agilent Technologies, Santa Clara, CA, USA). Genomic DNA (250 ng) from each tissue was sheared with Covaris S220 (Covaris, Woburn, MA, USA) and was used for the construction of a library using probes and the SureSelect XT reagent kit, HSQ (Agilent Technologies) according to the manufacturer’s protocol. As previously reported, this panel is designed to enrich exons of 83 genes covering 366.2 kb of the human genome [31]. After the enriched exome libraries were multiplexed, the libraries were sequenced using the HiSeq 2500 sequencing platform (Illumina, San Diego, CA, USA). Briefly, a paired-end DNA sequencing library was prepared through gDNA shearing, end-repair, A-tailing, paired-end adapter ligation, and amplification. After hybridization of the library with bait sequences for 27 hr, the captured library was purified and amplified with an index barcode tag, and the library’s quality and quantity...
were measured. Sequencing of the exome library was carried out using the 100 bp paired-end mode of the TruSeq Rapid PE Cluster kit and the TruSeq Rapid SBS kit (Illumina).

**Variant detection**

Sequence reads were mapped to the human genome (hg19) using the Burrows-Wheeler Aligner (BWA) [32]. Duplicate read removal was done using Picard (v1.93) and Samtools [33]. Local alignment was optimized using The Genome Analysis Toolkit (GATK) [34]. Variant calling was done only in targeted regions of the cancer panel. To detect single nucleotide variants, we integrated results of three kinds of variants caller [35–37], which increased sensitivity. We used a Pindel to detect insertions and deletions [38]. Copy number variations were calculated for targeted regions by dividing read-depth per exon by the estimated normal reads per exon using an in-house reference. Gene fusions in the target region were identified using an in-house algorithm.

**Digital droplet PCR**

Digital droplet PCR was performed on a QX200 ddPCR™ System (Bio-Rad, Hercules, CA, USA) platform. Briefly, ddPCR™ reaction mixes were prepared with template gDNAs, ddPCR™ Supermix (Bio-Rad), and TaqMan primer-probe mixtures and were partitioned into oil droplets (~20,000) generated by a QX200 droplet generator. The droplets were then thermal-cycled under the same condition described above using Veriti 96-Well Thermal Cycler (Life Technologies). Amplified droplets were imaged on a QX200 droplet reader (Bio-Rad) and analyzed by QuantaSoft™ software (Bio-Rad). The concentration of nucleic acid sequence targeted by the FAM and VIC or FAM and HEX dye labeled probes was estimated by Poisson distribution.

**Statistical analysis**

The Kaplan–Meier method was used for univariate analysis of survival outcomes. Survival outcomes were compared with the log-rank test. Overall survival was measured from the date of diagnosis to the date of death due to any cause and was censored at the date of the last follow-up visit. A two-sided P value < 0.05 was considered statistically significant.

**ACKNOWLEDGMENTS AND FUNDING**

This study was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (HI14C1324 and HI13C2096) and from Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2014R1A1A3050273).

**CONFLICTS OF INTEREST**

None.

**REFERENCES**

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008; 111:2962–2972.
2. Ludwig H, Sonneveld P, Davies F, Blade J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, et al. European perspective on multiple myeloma treatment strategies in 2014. Oncologist. 2014; 19:829–844.
3. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011; 364:1046–1060.
4. Ludwig H, Bolejack V, Crowley J, Blade J, Miguel JS, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westin J, Sonneveld P, Cavo M, Boccadoro M, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010; 28:1599–1605.
5. Kim SJ, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, Mun YC, Kim CS, Sohn SK, Eom HS, Kwak JY, Shim H, Yoon JH, et al. Korean Multiple Myeloma Working P. Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry. Acta Haematol. 2009; 122:200–210.
6. Hebraud B, Magrangeas F, Cleynen A, Lauwers-Cances V, Chretien ML, Hulin C, Leleu X, Yon E, Marit G, Karlin L, Roussel M, Stoppa AM, Belhadj K, et al. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood. 2015; 125:2095–2100.
7. Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JI, Marit G, Palumbo A, van der Holt B, Blade J, Petrucci MT, et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) in multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014; 32:2173–2180.
8. Lopez-Corral L, Corchete LA, Sarasquete ME, Mateos MV, Garcia-Sanz R, Ferrain E, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Blade J, Petrucci MT, et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014; 32:2173–2180.
9. Lopez-Corral L, Corchete LA, Sarasquete ME, Mateos MV, Garcia-Sanz R, Ferrain E, Lahuerta JJ, Blade J, Oriol A, Teruel AI, Martino ML, Hernandez J, Hernandez-Rivas JM, et al. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica. 2014; 99:1365–1372.
10. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007; 20:637–664.
11. Merlino G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011; 29:1924–1933.
11. Weinhold N, Forstl A, da Silva Filho MI, Nickel J, Campo C, Hoffmann P, Nothen MM, Hose D, Goldschmidt H, Jauch A, Langer C, Hegenbart U, Schonland SO, Hemminki K. Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma. Leukemia. 2014; 28:2254–2256.

12. Bochtler T, Hegenbart U, Heiss C, Benner A, Moos M, Seckinger A, Pschowski-Zuck S, Kirn D, Neben K, Bartram CR, Ho AD, Goldschmidt H, Hose D, et al. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gamopathy of undetermined significance and inversely associated with translocation t(11;14). Blood. 2011; 117:3809–3815.

13. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997.

14. Lohr JG, Stoianov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knocheil B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014; 25:91–101.

15. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J, Barlogie B. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000; 96:1505–1511.

16. Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawksa M, Chocholska S, Hajek R, Dmoszynska A. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol Oncol. 2013; 31:41–48.

17. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahlir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LJ, Scales M, Pawlyn C, et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol. 2015; 33:3911–3920.

18. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011; 2:344–358. doi: 10.1177/1947601911411084.

19. Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E, Rapp MJ, Harousseau JL, Moisan JP, Bataille R. High incidence of N- and K-ras in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat. 2001; 18:212–224.

20. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van Ness B. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood. 1996; 88:2699–2706.

21. Sclafani F, Gullo G, Sheahan K, Crown J. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications. Crit Rev Oncol Hematol. 2013; 87:55–68.

22. Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. 2014; 123:632–639.

23. Lee JY, Lim SH, Kim SJ, Lee GY, Lee JE, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K. Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. Amyloid. 2014; 21:261–266.

24. Jun HJ, Kim K, Kim SJ, Min YC, Bang SM, Won JH, Kim CS, Lee JH, Korean Multiple Myeloma Working P. Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: results of multicenter analysis. Am J Hematol. 2013; 88:52–55.

25. Kim SJ, Lee GY, Jang HR, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K. Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea. Amyloid. 2013; 20:204–211.

26. Egan JB, Shi CX, Tembe W, Christoforides A, Kuroglo A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats J, Fonseca R, Bergsagel PL, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012; 1060–1066.

27. Kortum KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jeddowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kulm M, et al. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in -17p high risk disease. Br J Haematol. 2015; 168:507–510.

28. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kaatrlies E, Richardson P, Landgren O, Paiva B, Dispensieri A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15:e538–548.

29. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23:3412–3420.

30. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2005; 23:3412–3420.

31. Park YH, Shin HT, Jung HH, Choi YL, Ahn T, Park K, Lee A, Do IG, Kim JY, Ahn JS, Park WY, Im YH. Role of HER2 mutations in refractory metastatic breast cancers:
targeted sequencing results in patients with refractory breast cancer. Oncotarget. 2015; 6:32027–32038. doi: 10.18632/oncotarget.5184.

32. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010; 26: 589–595.

33. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25:2078–2079.

34. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20:1297–1303.

35. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31:213–219.

36. Wilm A, Aw PP, Bertrand D, Yeo GH, Ong SH, Wong CH, Khor CC, Petric R, Hibberd ML, Nagarajan N. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012; 40:11189–11201.

37. Wei Z, Wang W, Hu P, Lyon GJ, Hakonarson H. SNVer: a statistical tool for variant calling in analysis of pooled or individual next-generation sequencing data. Nucleic Acids Res. 2011; 39:e132.

38. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics. 2009; 25:2865–2871.